

# ROCHE, Ocrelizumab: Long term safety and efficacy – Gaining confidence in positive Phase III readout

https://marketpublishers.com/r/R4EB4E0F8C2EN.html

Date: October 2011 Pages: 3 Price: US\$ 140.00 (Single User License) ID: R4EB4E0F8C2EN

## **Abstracts**

At European Committee of Treatment and Research in Multiple Sclerosis (ECTRIMS) 2011, Roche today announced the long term (96 weeks) safety and efficacy data from a PhII study on ocrelizumab in Relapsing Remitting Multiple Sclerosis (RRMS). The selected dose of ocrelizumab maintained its efficacy and safety profile from 24 wk to 96 wks. There were no cases of opportunistic infection which was the key concern with this drug, as earlier last year; a pivotal clinical study on Ocrelizumab in Rheumatoid Arthritis was discontinued due to increase in opportunistic infection (rate of serious infections - 3.54 and 8.66 per 100 patient year in the 200mg and 500mg doses). Cross trial efficacy and safety comparison of marketed and pipeline drugs in multiple sclerosis were analysed.



## **Contents**

#### **COMPANIES MENTIONED**

ROCHE



#### I would like to order

Product name: ROCHE, Ocrelizumab: Long term safety and efficacy – Gaining confidence in positive Phase III readout

Product link: https://marketpublishers.com/r/R4EB4E0F8C2EN.html

Price: US\$ 140.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/R4EB4E0F8C2EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



ROCHE, Ocrelizumab: Long term safety and efficacy - Gaining confidence in positive Phase III readout